Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
Oralee J Varnado,1 Brenna L Brady,2 Anthony J Zagar,1 Yvonne P Robles,2 Margaret Hoyt1 1Eli Lilly and Company, Indianapolis, IN, USA; 2Merative, Ann Arbor, MI, USACorrespondence: Oralee J VarnadoValue, Evidence, and Outcomes, Eli Lilly and Company, Lilly Corporate Center, 893 Delaware Street, Indian...
Main Authors: | Varnado OJ, Brady BL, Zagar AJ, Robles YP, Hoyt M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2024-01-01
|
Series: | Patient Preference and Adherence |
Subjects: | |
Online Access: | https://www.dovepress.com/comparison-of-treatment-patterns-in-patients-with-migraine-initiating--peer-reviewed-fulltext-article-PPA |
Similar Items
-
Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
by: Licia Grazzi, et al.
Published: (2024-02-01) -
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
by: Antun R. Pavelic, et al.
Published: (2022-12-01) -
Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review
by: Theodoros Mavridis, et al.
Published: (2019-01-01) -
Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
by: Larry Charleston, et al.
Published: (2023-08-01) -
Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal
by: Yan Tereshko, et al.
Published: (2023-11-01)